References
- VogelmeierCFCrinerGJMartinezFJGlobal Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 report: GOLD executive summaryAm J Respir Crit Care Med2017195555758228128970
- HurstJRVestboJAnzuetoASusceptibility to exacerbation in chronic obstructive pulmonary diseaseN Engl J Med2010363121128113820843247
- KeeneJDJacobsonSKechrisKBiomarkers predictive of exacerbations in the SPIROMICS and COPDGene CohortsAm J Respir Crit Care Med2017195447348127579823
- WedzichaJASinghDVestboJExtrafine beclomethasone/formoterol in severe COPD patients with history of exacerbationsRespir Med201410881153116224953015
- CalverleyPMBoonsawatWCsekeZZhongNPetersonSOlssonHMaintenance therapy with budesonide and formoterol in chronic obstructive pulmonary diseaseEur Respir J200322691291914680078
- SharafkhanehASouthardJGGoldmanMUryniakTMartinUJEffect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized studyRespir Med2012106225726822033040
- CalverleyPMMinimal clinically important difference: exacerbations of COPDCOPD20052114314817136975
- HanMKMuellerovaHCurran-EverettDGOLD 2011 disease severity classification in COPDGene: a prospective cohort studyLancet Respir Med201311435024321803
- LawrencePJKolsumUGuptaVCharacteristics and longitudinal progression of chronic obstructive pulmonary disease in GOLD B patientsBMC Pulm Med20171714228219428
- VestboJEdwardsLDScanlonPDChanges in forced expiratory volume in 1 second over time in COPDN Engl J Med2011365131184119221991892
- SinghDPharmacological treatment for COPD: GOLD 2017 changes directionBr J Clin Pharmacol201783593593728295508